CI outside 80.00%–125.00%, who cares? [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2011-10-11 11:54 (5376 d 11:16 ago) – Posting: # 7467
Views: 5,042

Dear Helmut

    → 80.00–125.00 ![/b]

  Cave: Keine Einreichung wenn Grenzen

  überschritten → EU weit: null Akzeptanz !!

❝ Of course this deals with IR, but nice to know.


To be honest, we submitted this year a bioequivalence study for an IR formulation of a well known uncomplicated drug with following results:

upper confidence interval limit for Cmax slightly out of acceptance range
Results for AUC and Cmax ratios opposit => complete different kinetic in comparison to the originator
Point estimator shows a difference > 15% => narrow confidence interval due to high subject number and very low intra-subject variability.

I was convinced that we would have been slaughtered by the regulatory authorities, but what a surprise we got the marketing authorisation. RMS = Germany (BfArM). In fact the assessor did not care about the acceptance criteria layed down in the guideline. He just judged the clinical impact. So we are far away from a consistent assessment.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
325 visitors (0 registered, 325 guests [including 19 identified bots]).
Forum time: 23:10 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5